Related references
Note: Only part of the references are listed.KNK437 Downregulates Heat Shock Protein 27 of Pancreatic Cancer Cells and Enhances the Cytotoxic Effect of Gemcitabine
Kumiko Taba et al.
CHEMOTHERAPY (2011)
Quinacrine Enhances Cisplatin-Induced Cytotoxicity in Four Cancer Cell Lines
Yixiang Wang et al.
CHEMOTHERAPY (2010)
The Glasgow Prognostic Score Is a Good Predictor of Treatment Outcome in Patients with Unresectable Pancreatic Cancer
Mitsugi Shimoda et al.
CHEMOTHERAPY (2010)
Synergistic Cytotoxicity and Molecular Interaction on Drug Targets of Sorafenib and Gemcitabine in Human Pancreas Cancer Cells
Simona Ricciardi et al.
CHEMOTHERAPY (2010)
Carbohydrate Antigen 19-9 Change During Chemotherapy for Advanced Pancreatic Adenocarcinoma
Michele Reni et al.
CANCER (2009)
Weekly Epirubicin as Salvage Therapy in Patients with Gemcitabine-Resistant Advanced Pancreatic Cancer
S. Cereda et al.
JOURNAL OF CHEMOTHERAPY (2009)
PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy
M. Reni et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2008)
A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma
M. Reni et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Efficacy of gemcitabine for locally advanced pancreatic cancer: Comparison with 5-fluorouracil-based chemoradiotherapy
Minoru Tada et al.
CHEMOTHERAPY (2008)
Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer
S. Cereda et al.
JOURNAL OF CHEMOTHERAPY (2008)
BRCA1 p.Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from northeast Italy
Sandro Malacrida et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer
Matthew H. Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study
Akira Togawa et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase II study of docetaxel in combination with ZD1839 (gefitinib) in previously treated patients with metastatic pancreatic cancer
L. S. Blaszkowsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer:: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
Richard Herrmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer:: a multicenter phase II trial
S. Boeck et al.
ANNALS OF ONCOLOGY (2007)
Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: Novel pathways and targets for anticancer therapeutics
Rachel E. Airley et al.
CHEMOTHERAPY (2007)
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer
Stefan Boeck et al.
ONCOLOGY (2007)
Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer
M Reni et al.
BRITISH JOURNAL OF CANCER (2006)
Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
A Demols et al.
BRITISH JOURNAL OF CANCER (2006)
Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study
N Tsavaris et al.
INVESTIGATIONAL NEW DRUGS (2005)
Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial
M Reni et al.
LANCET ONCOLOGY (2005)
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer:: Results of a GERCOR and GISCAD phase III trial
C Louvet et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II trial of oral rubitecan in previously treated pancreatic cancer patients
HA Burris et al.
ONCOLOGIST (2005)
Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: A prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology
M Cantore et al.
JOURNAL OF CHEMOTHERAPY (2004)
Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer
M Cantore et al.
ONCOLOGY (2004)
Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group
MJ Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma
H Ulrich-Pur et al.
BRITISH JOURNAL OF CANCER (2003)
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297
JD Berlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma
H Oettle et al.
ANTI-CANCER DRUGS (2000)
Share Paper
